Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.
作者信息
Karanfilian Briette, Dalal Ishita, Bhurwal Abhishek, Patel Anish Vinit
机构信息
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Division of Gastroenterology & Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
出版信息
Am J Ther. 2020 Jul/Aug;27(4):e415-e417. doi: 10.1097/MJT.0000000000001165.
PMID:32355083
Abstract
摘要
相似文献
1
Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.英夫利昔单抗治疗同时使用伊匹单抗和纳武单抗导致的免疫介导性结肠炎
Am J Ther. 2020 Jul/Aug;27(4):e415-e417. doi: 10.1097/MJT.0000000000001165.
2
Infliximab for severe colitis associated with nivolumab followed by ipilimumab.英夫利昔单抗用于治疗与纳武单抗随后伊匹单抗相关的严重结肠炎。
J Dermatol. 2018 Jan;45(1):e1-e2. doi: 10.1111/1346-8138.14034. Epub 2017 Sep 11.
3
Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.接受伊匹单抗和纳武利尤单抗联合治疗或单药治疗的患者的胃肠道并发症。
J Comp Eff Res. 2019 Jan;8(2):81-90. doi: 10.2217/cer-2018-0072. Epub 2018 Dec 14.
4
Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药治疗对亚洲IV期黑色素瘤患者的真实世界疗效
Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139.
5
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.免疫检查点抑制剂相关性结肠炎治疗中使用英夫利昔单抗导致的急性肝损伤。
J Immunother Cancer. 2019 Feb 18;7(1):47. doi: 10.1186/s40425-019-0532-1.
6
Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.英夫利昔单抗单剂治疗伊匹单抗和纳武利尤单抗相关严重结肠炎：完全缓解
Rev Esp Enferm Dig. 2020 Nov;112(11):889-890. doi: 10.17235/reed.2020.6886/2020.
7
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.单药或双药免疫检查点抑制剂作为晚期黑色素瘤的辅助治疗
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
8
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药对比伊匹单抗单药一线治疗晚期黑色素瘤患者的生存质量调整：无疾病或毒性生存时间（Q-TWiST）分析。
Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.
9
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.免疫检查点抑制剂治疗后并发神经结节病的迟发性发作。
J Immunother Cancer. 2018 Jul 31;6(1):77. doi: 10.1186/s40425-018-0390-2.
10
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.联合 ipilimumab 和 nivolumab 一线治疗及 BRAF 靶向治疗后在晚期黑色素瘤中的应用。
Pigment Cell Melanoma Res. 2020 Mar;33(2):358-365. doi: 10.1111/pcmr.12831. Epub 2019 Nov 2.
Zotero 插件